Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2022/10/046427
CTRI/2022/10/046427
Not yet recruiting
未知

A prospective study to assess the impact of pharmacist-led patient-centered interventions in schizophrenia - NI

Dr Deepak C G0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: F209- Schizophrenia, unspecified

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: F209- Schizophrenia, unspecified
Sponsor
Dr Deepak C G
Status
Not yet recruiting
Last Updated
3 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
Dr Deepak C G

Eligibility Criteria

Inclusion Criteria

  • •Patient or caretaker
  • •Patient or caretaker willing to provide informed consent
  • •Patients aged ââ?°Â¥ 18 and ââ?°Â¤ 65 years old
  • •Patients diagnosed with schizophrenia and schizophrenia spectrum disorders who were on the treatment of antipsychotic drugs with or without co\-morbidities of hypertension, diabetes, hypercholesterolemia and weight gain
  • •Both genders

Exclusion Criteria

  • •Patient or caretaker unwilling to provide consent
  • •Patients with other severe chronic medical conditions, including cancer, end\-stage renal disease, heart failure and HIV
  • •Patients with a diagnosis of Cushing syndrome, hypothyroidism, eating disorder
  • •Patients who are engaged in the weight management programs within the past 3 months
  • •Patients who are taking other forms of medicines to control weight including Ayurvedha, Homeopathy
  • •Patients with co\-existing physical illnesses that reduce their ability to participate in the study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Pharmacogenetic Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant PatientsRenal TransplantationMedDRA version: 19.0Level: LLTClassification code 10023438Term: Kidney transplantSystem Organ Class: 100000004865Therapeutic area: Body processes [G] - Immune system processes [G12]
EUCTR2016-001042-25-Outside-EU/EEAF. Hoffmann-La Roche AG720
Completed
Phase 3
Impact of Belly Board on small bowel toxicity in carcinoma cervixHealth Condition 1: C539- Malignant neoplasm of cervix uteri, unspecified
CTRI/2020/10/028235SVIMS28
Not yet recruiting
Not Applicable
An intervention study for influenza prevention among school childreinfluenza
JPRN-UMIN000039022iigata University160
Not yet recruiting
Not Applicable
A study to capture the side effects and Quality of life(QoL) in castration-resistant prostate cancer patients who are receiving docetaxel as part of standard therapy in Tata Memorial Centre.Health Condition 1: C61- Malignant neoplasm of prostate
CTRI/2019/09/021080Tata Memorial Centre
Completed
Phase 2
Prospective study of efficacy, safety and pharmacokinetics of transcatheter arterial chemoembolization (TACE) with miriplatin for hepatocellular carcinoma.Hepatocellular carcinoma (HCC)
JPRN-UMIN000006926Kawasaki Medical School20